Annika Kim Constantino
Annika Kim Constantino focuses on how major drugmakers, biotech firms and health insurers turn scientific developments and policy shifts into business results and market moves. She is a health and pharmaceutical reporter at CNBC, covering the biotech and pharmaceutical industry for the network’s digital platforms. Her coverage sits at the intersection of medicine, corporate strategy and investor reaction, with recurring attention to obesity treatments, cancer therapies and government-backed insurance programs.
Obesity drugs and big pharma earnings
Much of Constantino’s recent work follows the rise of obesity medicines and the companies competing to dominate that market. She regularly covers Novo Nordisk and Eli Lilly, tracking how demand for GLP‑1 drugs and new weight loss pills translates into revenue growth, guidance changes and volatile share prices.
Her reporting on Novo Nordisk’s rebrand to “Novo” under CEO Mike Doustdar ties branding and corporate culture directly to the company’s fight to regain obesity market share, treating the rebrand as a business decision shaped by the obesity landscape rather than a cosmetics exercise.
Constantino’s television segments on Novo Nordisk’s weight loss pill and related GLP‑1 products emphasize both the pipeline and the patient base, explaining how oral medicines are drawing new patients into obesity treatment while reshaping expectations for long‑term demand. Earnings coverage for Eli Lilly highlights the company’s “winning streak,” connecting quarterly results to the performance of its obesity and diabetes portfolio and to investor sentiment around future launches. These stories show her preference for tying drug performance and clinical developments back to guidance, market share and stock moves, rather than treating them as isolated scientific updates.
Biotech breakthroughs and late‑stage trials
Beyond obesity, Constantino focuses on late‑stage trial results and breakthrough therapies in oncology and respiratory disease. Her reporting on AstraZeneca’s COPD drug tozorakimab details the magnitude of trial wins in clear metric terms, citing reductions of moderate and severe exacerbations while situating those results against existing inhaled standards of care.
She presents those data points alongside discussion of “blockbuster hopes,” showing an interest in how trial outcomes feed into commercial potential and pipeline valuation.
Constantino’s coverage of Moderna and Merck’s experimental cancer vaccine similarly connects late‑stage trial success to sharp moves in both companies’ shares. On air, she breaks down why the trial’s design and endpoints matter to investors, explaining how positive data can nearly double a stock or trigger a broader re‑rating of a company’s oncology franchise.
Across these pieces, she treats clinical trial results as inflection points for business strategy and market positioning, rather than purely scientific milestones.
Health insurers, government programs and cost pressure
Constantino also follows how health insurers respond to changing economics in government‑backed programs such as Medicaid, Medicare and Affordable Care Act plans. In her piece on Centene’s decision to offer buyouts to employees as the insurer cuts costs, she links a voluntary separation program to broader pressures from higher medical costs, funding cuts and membership declines.
She walks through how the expiration of enhanced ACA subsidies contributed to a roughly 6% year‑over‑year decline in total membership and a steep drop in ACA enrollment, then connects those trends to Centene’s expectation that ACA membership could fall nearly 40% by the end of 2026.
The Centene story illustrates her approach to insurer coverage: close attention to filings and executive commentary, clear reporting on workforce actions, and explicit tracking of how policy changes ripple through enrollment and earnings. She notes immediate share price reactions and flags the prospect of layoffs if voluntary separations do not meet internal targets, underscoring how operational restructuring and labor decisions are tied to financial performance and market confidence.
Her insurer reporting keeps government program mechanics in view while focusing on what they mean for corporate strategy and investor risk.
Digital reporting and on‑air analysis
Constantino works across digital and broadcast formats, using quick, data‑rich segments to extend her written coverage of pharmaceutical and biotech companies. She appears on the network’s news programs to discuss earnings, trial results and corporate announcements, offering concise explanations of why a single headline can move a stock sharply higher or lower. Her interviews with executives, including a sit‑down with Novo’s CEO about the company’s rebrand and shift in corporate culture, keep the conversation anchored in strategic decisions and market share rather than personal narratives.
Across mediums, Constantino’s reporting is consistent in tone: short, direct explanations of complex health‑care topics with clear links to revenue, guidance, shareholder reaction and competitive dynamics. She returns to the same set of themes - obesity treatments, oncology and respiratory pipelines, insurer exposure to government programs - building a beat that treats health care companies as both scientific and financial actors. That combination of clinical detail and market focus distinguishes her from more general health or finance reporters who cover these stories from only one of those angles.
4 more finance journalists.
Abigail Summerville
Abigail Summerville brings a leveraged finance background to her work covering consumer and retail mergers and acquisitions for Reuters. She reports on deal-making and capital markets across food, beverages, spirits, personal care, skincare, bath products and pet food. Her stories focus on transaction terms, ownership stakes, valuation, debt structures and funding sources. She often breaks news on potential sales and strategic reviews before formal announcements. Notable coverage includes Sazerac’s acquisition of Au Vodka, Blackstone’s exploration of a ZO Skin Health sale, CVC’s efforts to sell the parent of Dr Teal’s, and Colgate-Palmolive’s planned divestitures. She also covers consumer IPOs, including Jersey Mike’s and Black Rock Coffee, and co-writes Wall Street market reports. She joined Reuters in 2022 after three years covering leveraged finance and primary debt markets.
Adekunle Agbetiloye
Adekunle Agbetiloye is a senior reporter who connects capital flows, hard numbers and energy transition to the wider African economy. He works at Business Insider Africa, covering how money, technology and energy reshape economic growth, jobs and living conditions. His beat spans the African economy, technology, energy transition, climate change, startups and critical minerals, with a focus on concrete deals and data-led stories. He reports on African startup funding cycles, sovereign wealth funds, billionaire investors, multilateral and private investment programs, energy and power markets, Bitcoin mining, and economic policy choices. His work follows how governments finance spending, manage debt and respond to social pressure, and how sector snapshots and health and development metrics reveal links between macro indicators, corporate strategy and everyday costs.
Aimee Picchi
Aimee Picchi connects Social Security, retirement programs and economic policy directly to the financial security of ordinary Americans, showing how macro decisions hit household budgets. She is associate managing editor for CBS MoneyWatch at CBS News, covering business and personal finance with clear, accessible explanations of complex money issues. Her core beat is Social Security and retirement, interest rates and inflation, and how policy, markets and company strategies affect workers, retirees, savers and investors. She reports on benefit adequacy, looming Social Security cuts, COLA changes, Federal Reserve rate decisions, fuel costs, trade tensions and labor’s share of income, always framing coverage around pocketbook impacts. Her background includes retirement reporting fellowships, prior staff reporting on technology, media and business, an Institutional Investor book on affluent investors, and freelance work for national outlets. She also writes science fiction and fantasy and is a Nebula Award finalist.
Alex Harring
Alex Harring turns fast-moving market, economic and corporate developments into clear pre-market briefings that show what will matter when U.S. trading opens. He is a markets and economics reporter for CNBC’s digital platforms and writes Morning Squawk, a flagship daily newsletter that gives readers five key things to know before the stock market opens. His beat spans financial markets, investing, consumer trends and the U.S. economy, with coverage of central bank decisions, inflation, corporate strategy, sector moves and geopolitical shocks. He focuses on how policy, data and earnings shape equities, interest rates, currencies and investor positioning, linking price action with underlying drivers in real time and in reported features. Harring’s background reporting on corporate news, business and the economy across print, digital, broadcast and streaming informs his habit of connecting markets, companies and geopolitics in one frame.